#msg-55725398 has a quiz that’s easy enough for almost anyone on this board to get the answer, while still being hard enough to make one have to think. Any takers?
GILD thinks that high rate of virological failure seen in the completed phase-3 trials could have resulted from low compliance of patients, who had to take many pills a day (trials were double blinded and placebo controlled). In the new Bitripla vs.Atripla every one gets fixed-dose once a day and I believe the B is a smaller pill than A (because TMC278 25 mg is smaller than 600 mg for Sustiva), so it's an open trial and everyone knows what they are getting.
Market Data 
Markets 
AI
